Premium
Suppressive effect of saprogrelate hydrochloride on Raynaud’s phenomenon and respiratory failure in patients with systemic sclerosis
Author(s) -
Kato Shiro,
Kishiro Izumi,
Ohnuma Noboru,
Takasaki Keiji,
Okamoto Shingo,
Nakamoto Takaaki,
Kaneko Noboru,
Kumamoto Hidero
Publication year - 2000
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1046/j.1440-1843.2000.00222.x
Subject(s) - medicine , respiratory system , scleroderma (fungus) , raynaud disease , progressive systemic sclerosis , dermatology , cardiology , pathology , inoculation
Objective : In seven patients with systemic sclerosis (SS), we evaluated the clinical effectiveness of oral administration of saprogrelate hydrochloride (SH: 300 mg/day) for 2 months on Raynaud’s phenomenon (RP) and respiratory failure estimated by Hugh‐Jones classification.Methodology : We evaluated laboratory data (arterial blood gas (pH, P a O 2 and P a CO 2 ), pulmonary function tests (%VC, FEV 1 /FVC and %DL co ), mean pulmonary arterial pressure (mPAP), white blood cell count, C‐reactive protein and the plasma levels of fibrinopeptide A (FPA), β‐thrombogloblin (β‐TG), platelet factor 4 (PF4) and thrombomodulin (TM)) before and after SH administration.Results : The frequency and duration of RP, as well as the coldness, numbness and pain of RP were significantly decreased after SH administration ( P < 0.05, P < 0.01 and P < 0.001). Respiratory failure estimated by Hugh‐Jones classification was also significantly decreased after SH administration ( P < 0.05), and the %DL co was significantly increased ( P < 0.01). The mPAP decreased significantly after SH administration ( P < 0.05). Plasma FPA, β‐TG and PF4 significantly decreased after administration ( P < 0.05 and P < 0.01).Conclusions : SH therapy could prevent RP and respiratory failure in patients with SS.